Answers are grounded in this paper and cite their sources.
Cytogenetics, which has already shown itself to be an essential adjunct to conventional diagnostic pathology and an independent prognostic factor in the leukemias, will increasingly take on the same role vis-à-vis solid tumors. A primary goal is to reduce the diversity of chromosomal anomalies and cytogenetic events in solid tumors to a clinically manageable and pertinent framework.
No takes yet. Share an insight, caveat, or question.
Avery A. Sandberg (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: